Pharmaceuticals firm Nostrum Laboratories and its founder and chief executive officer could pay up to $50 million as part of a settlement with the Department of Justice (DOJ) addressing alleged violations of the False Claims Act by underpaying Medicaid rebates.
Nostrum and CEO Nirmal Mulye agreed to pay at least $3.8 million, with the remainder of the settlement total to be determined based on their respective financial conditions, the DOJ announced in a press release Monday. Portions of the remaining money would be split among Medicaid-participating states as part of separate settlements, according to the agency’s settlement agreement.
